Cargando…

Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study

Determination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is important in guiding the infection control and differentiating between reinfection and persistent viral RNA. Although viral culture is the gold standard to determine viral infectivity, the method is not prac...

Descripción completa

Detalles Bibliográficos
Autores principales: Phuphuakrat, Angsana, Pasomsub, Ekawat, Srichatrapimuk, Sirawat, Kirdlarp, Suppachok, Suksatu, Ampa, Srisaowakarn, Chanya, Manopwisedjaroen, Suwimon, Ludowyke, Natali, Purwono, Priyo Budi, Priengprom, Thongkoon, Wongsa, Artit, Thakkinstian, Ammarin, Hongeng, Suradej, Malathum, Kumthorn, Thitithanyanont, Arunee, Tassaneetrithep, Boonrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241878/
https://www.ncbi.nlm.nih.gov/pubmed/35604133
http://dx.doi.org/10.1128/spectrum.00503-22
_version_ 1784737921907032064
author Phuphuakrat, Angsana
Pasomsub, Ekawat
Srichatrapimuk, Sirawat
Kirdlarp, Suppachok
Suksatu, Ampa
Srisaowakarn, Chanya
Manopwisedjaroen, Suwimon
Ludowyke, Natali
Purwono, Priyo Budi
Priengprom, Thongkoon
Wongsa, Artit
Thakkinstian, Ammarin
Hongeng, Suradej
Malathum, Kumthorn
Thitithanyanont, Arunee
Tassaneetrithep, Boonrat
author_facet Phuphuakrat, Angsana
Pasomsub, Ekawat
Srichatrapimuk, Sirawat
Kirdlarp, Suppachok
Suksatu, Ampa
Srisaowakarn, Chanya
Manopwisedjaroen, Suwimon
Ludowyke, Natali
Purwono, Priyo Budi
Priengprom, Thongkoon
Wongsa, Artit
Thakkinstian, Ammarin
Hongeng, Suradej
Malathum, Kumthorn
Thitithanyanont, Arunee
Tassaneetrithep, Boonrat
author_sort Phuphuakrat, Angsana
collection PubMed
description Determination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is important in guiding the infection control and differentiating between reinfection and persistent viral RNA. Although viral culture is the gold standard to determine viral infectivity, the method is not practical. We studied the kinetics of SARS-CoV-2 total RNAs and subgenomic RNAs (sgRNAs) and their potential role as surrogate markers of viral infectivity. The kinetics of SARS-CoV-2 sgRNAs compared to those of the culture and total RNA shedding in a prospective cohort of patients diagnosed with coronavirus disease 2019 (COVID-19) were investigated. A total of 260 nasopharyngeal swabs from 36 patients were collected every other day after entering the study until the day of viral total RNA clearance, as measured by reverse transcription PCR (RT-PCR). Time to cessation of viral shedding was in order from shortest to longest: by viral culture, sgRNA RT-PCR, and total RNA RT-PCR. The median time (interquartile range) to negativity of viral culture, subgenomic N transcript, and N gene were 7 (5 to 9), 11 (9 to 16), and 18 (13 to 21) days, respectively (P < 0.001). Further analysis identified the receipt of steroid as the factors associated with longer duration of viral infectivity (hazard ratio, 3.28; 95% confidence interval, 1.02 to 10.61; P = 0.047). We propose the potential role of the detection of SARS-CoV-2 subgenomic RNA as the surrogate marker of viral infectivity. Patients with negative subgenomic N RNA RT-PCR could be considered for ending isolation. IMPORTANCE Our study, combined with existing evidence, suggests the feasibility of the use of subgenomic RNA RT-PCR as a surrogate marker for SARS-CoV-2 infectivity. The kinetics of SARS-CoV-2 subgenomic RNA should be further investigated in immunocompromised patients.
format Online
Article
Text
id pubmed-9241878
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-92418782022-06-30 Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study Phuphuakrat, Angsana Pasomsub, Ekawat Srichatrapimuk, Sirawat Kirdlarp, Suppachok Suksatu, Ampa Srisaowakarn, Chanya Manopwisedjaroen, Suwimon Ludowyke, Natali Purwono, Priyo Budi Priengprom, Thongkoon Wongsa, Artit Thakkinstian, Ammarin Hongeng, Suradej Malathum, Kumthorn Thitithanyanont, Arunee Tassaneetrithep, Boonrat Microbiol Spectr Research Article Determination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is important in guiding the infection control and differentiating between reinfection and persistent viral RNA. Although viral culture is the gold standard to determine viral infectivity, the method is not practical. We studied the kinetics of SARS-CoV-2 total RNAs and subgenomic RNAs (sgRNAs) and their potential role as surrogate markers of viral infectivity. The kinetics of SARS-CoV-2 sgRNAs compared to those of the culture and total RNA shedding in a prospective cohort of patients diagnosed with coronavirus disease 2019 (COVID-19) were investigated. A total of 260 nasopharyngeal swabs from 36 patients were collected every other day after entering the study until the day of viral total RNA clearance, as measured by reverse transcription PCR (RT-PCR). Time to cessation of viral shedding was in order from shortest to longest: by viral culture, sgRNA RT-PCR, and total RNA RT-PCR. The median time (interquartile range) to negativity of viral culture, subgenomic N transcript, and N gene were 7 (5 to 9), 11 (9 to 16), and 18 (13 to 21) days, respectively (P < 0.001). Further analysis identified the receipt of steroid as the factors associated with longer duration of viral infectivity (hazard ratio, 3.28; 95% confidence interval, 1.02 to 10.61; P = 0.047). We propose the potential role of the detection of SARS-CoV-2 subgenomic RNA as the surrogate marker of viral infectivity. Patients with negative subgenomic N RNA RT-PCR could be considered for ending isolation. IMPORTANCE Our study, combined with existing evidence, suggests the feasibility of the use of subgenomic RNA RT-PCR as a surrogate marker for SARS-CoV-2 infectivity. The kinetics of SARS-CoV-2 subgenomic RNA should be further investigated in immunocompromised patients. American Society for Microbiology 2022-05-23 /pmc/articles/PMC9241878/ /pubmed/35604133 http://dx.doi.org/10.1128/spectrum.00503-22 Text en Copyright © 2022 Phuphuakrat et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Phuphuakrat, Angsana
Pasomsub, Ekawat
Srichatrapimuk, Sirawat
Kirdlarp, Suppachok
Suksatu, Ampa
Srisaowakarn, Chanya
Manopwisedjaroen, Suwimon
Ludowyke, Natali
Purwono, Priyo Budi
Priengprom, Thongkoon
Wongsa, Artit
Thakkinstian, Ammarin
Hongeng, Suradej
Malathum, Kumthorn
Thitithanyanont, Arunee
Tassaneetrithep, Boonrat
Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
title Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
title_full Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
title_fullStr Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
title_full_unstemmed Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
title_short Detectable Duration of Viable SARS-CoV-2, Total and Subgenomic SARS-CoV-2 RNA in Noncritically Ill COVID-19 Patients: a Prospective Cohort Study
title_sort detectable duration of viable sars-cov-2, total and subgenomic sars-cov-2 rna in noncritically ill covid-19 patients: a prospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241878/
https://www.ncbi.nlm.nih.gov/pubmed/35604133
http://dx.doi.org/10.1128/spectrum.00503-22
work_keys_str_mv AT phuphuakratangsana detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT pasomsubekawat detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT srichatrapimuksirawat detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT kirdlarpsuppachok detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT suksatuampa detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT srisaowakarnchanya detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT manopwisedjaroensuwimon detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT ludowykenatali detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT purwonopriyobudi detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT priengpromthongkoon detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT wongsaartit detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT thakkinstianammarin detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT hongengsuradej detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT malathumkumthorn detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT thitithanyanontarunee detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy
AT tassaneetrithepboonrat detectabledurationofviablesarscov2totalandsubgenomicsarscov2rnainnoncriticallyillcovid19patientsaprospectivecohortstudy